1. Cancer Stem Cells in Soft-Tissue Sarcomas
- Author
-
Paula Martinez-Delgado, David S. Moura, Elena Blanco-Alcaina, Javier Martin-Broto, Jose L. Mondaza-Hernandez, Antònia Obrador-Hevia, Serena Lacerenza, Paloma Sanchez-Bustos, Maria Lopez-Alvarez, Nadia Hindi, [Martínez-Delgado,P, Lacerenza,S, Lopez-Alvarez,M, Mondaza-Hernandez,JL, Blanco-Alcaina,E, Sanchez-Bustos,P, Hindi,N, Moura,DS, Martin-Broto,J] Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain. [Obrador-Hevia,A] Health Research Institute of the Balearic Islands (IdISBa) and Molecular Diagnosis Unit, Son Espases University Hospital, Palma de Mallorca, Spain. [Hindi, and Martin-Broto,J] Medical Oncology Department, University Hospital Virgen del Rocio, Seville, Spain.
- Subjects
cancer stem cells ,chemotherapy resistance ,Phenomena and Processes::Genetic Phenomena::Phenotype [Medical Subject Headings] ,sarcoma ,humanos ,Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma [Medical Subject Headings] ,Anatomy::Cells::Stem Cells::Neoplastic Stem Cells [Medical Subject Headings] ,Review ,Tumor initiation ,Drug resistance ,medicine.disease_cause ,genetic and epigenetic plasticity ,Metastasis ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Mice ,Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm [Medical Subject Headings] ,tumor heterogeneity ,Organisms::Eukaryota::Animals [Medical Subject Headings] ,Stemness ,lcsh:QH301-705.5 ,Cancer stem cells ,Genetic and epigenetic plasticity ,Soft tissue sarcoma ,Tumor-initiating cells ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Neoplastic Processes::Carcinogenesis [Medical Subject Headings] ,Sarcoma ,General Medicine ,soft-tissue sarcoma ,Neoplastic Stem Cells ,Soft-tissue sarcoma ,Chemotherapy resistance ,células madre neoplásicas ,Tumor heterogeneity ,tumor-initiating cells ,stemness ,Cancer stem cell ,medicine ,Animals ,Humans ,Células madre neoplásicas ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings] ,business.industry ,Mesenchymal stem cell ,medicine.disease ,lcsh:Biology (General) ,Tumor progression ,Cancer research ,animales ,Carcinogenesis ,business ,ratones - Abstract
This article belongs to the Special Issue Cancer Stem Cells and Resistance to Therapy., Soft tissue sarcomas (STS) are a rare group of mesenchymal solid tumors with heterogeneous genetic profiles and clinical features. Systemic chemotherapy is the backbone treatment for advanced STS; however, STS frequently acquire resistance to standard therapies, which highlights the need to improve treatments and identify novel therapeutic targets. Increases in the knowledge of the molecular pathways that drive sarcomas have brought to light different molecular alterations that cause tumor initiation and progression. These findings have triggered a breakthrough of targeted therapies that are being assessed in clinical trials. Cancer stem cells (CSCs) exhibit mesenchymal stem cell (MSC) features and represent a subpopulation of tumor cells that play an important role in tumor progression, chemotherapy resistance, recurrence and metastasis. In fact, CSCs phenotypes have been identified in sarcomas, allied to drug resistance and tumorigenesis. Herein, we will review the published evidence of CSCs in STS, discussing the molecular characteristic of CSCs, the commonly used isolation techniques and the new possibilities of targeting CSCs as a way to improve STS treatment and consequently patient outcome.
- Published
- 2020